{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:22:52Z","timestamp":1747207372838,"version":"3.40.5"},"reference-count":37,"publisher":"Bentham Science Publishers Ltd.","issue":"13","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Iron-chelation therapy is life-saving in patients on a chronic transfusion regimen as it reduces organ damage related to iron deposition in the tissues. Deferasirox, an iron-chelator, is characterized by pharmacokinetics variability, and some patients may discontinue the treatment due to toxicities.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>Understanding whether deferasirox plasma levels are related to patients' specific characteristics could help optimize DFX dosage.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>We analyzed deferasirox plasma concentration in 57 transfusion-dependent anemic patients using the HPLC method in this prospective-retrospective cohort study. All outpatients (3 to 98 years) were treated with deferasirox (film-coated tablet) for at least one year (median dose, 16.5 mg\/Kg once a day). Deferasirox plasma concentration was normalized for dose\/Kg (C\/dose) and corrected with a linear regression model that relates C\/dose and the time of blood sampling (Cref\/dose).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>No significant differences in Cref\/dose were found between males and females, either between different types of hemoglobinopathies or depending on the presence of the UGT1A1*28 polymorphism. Cref\/dose has a positive and significant correlation with age, creatinine, and direct bilirubin. Cref\/dose, instead, has a negative and significant correlation with Liver Iron Concentration (LIC), ferritin, and eGFR. Cref\/dose was significantly different between three age categories &lt;18yrs, 18-50yrs, and &gt;50yrs, with Cref\/dose median values of 1.0, 1.2, and 1.5, respectively.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The study evidenced that to ensure the efficacy of deferasirox in terms of control over LIC and, at the same time, a lesser influence on renal function, the dose of the drug to be administered to an elderly patient could be reduced.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389200224666221209144420","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T05:54:37Z","timestamp":1670824477000},"page":"1072-1079","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Aging on Deferasirox Therapy in Transfusion-dependent Patients. A Prospective-\nRetrospective, Cohort-study"],"prefix":"10.2174","volume":"23","author":[{"given":"Valeria","family":"Marini","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Unit, EO Ospedali Galliera, Mura delle Cappuccine, n. 14. I-16128 Genoa, Italy"},{"name":"Department of Internal\nMedicine, Clinical Pharmacology and Toxicology Unit, University of Genoa, Viale Benedetto XV, n. 2. I-16132 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria Maria","family":"Pinto","sequence":"additional","affiliation":[{"name":"Centro\ndella Microcitemia, Anemie Congenite e Dismetabolismo del Ferro, EO Ospedali Galliera, Mura delle Cappuccine, n. 14. I-16128\nGenoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Stella","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, EO Ospedali Galliera, Mura delle Cappuccine, n. 14. I-16128 Genoa, Italy"},{"name":"Department of Internal\nMedicine, Clinical Pharmacology and Toxicology Unit, University of Genoa, Viale Benedetto XV, n. 2. I-16132 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Fucile","sequence":"additional","affiliation":[{"name":"Unit of Addiction and Hepatology, Alcohological Regional Center, ASL3 San Martino Hospital, Largo R. Benzi, n. 10,\nI-16132 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Lantieri","sequence":"additional","affiliation":[{"name":"Health Science Department, Biostatistics Unit, University of Genoa, Via Pastore, n. 1. I-16132 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Luci","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa, Via Savi, n.10. I-56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Gianesin","sequence":"additional","affiliation":[{"name":"Centro\ndella Microcitemia, Anemie Congenite e Dismetabolismo del Ferro, EO Ospedali Galliera, Mura delle Cappuccine, n. 14. I-16128\nGenoa, Italy"},{"name":"For Anemia Foundation,\nVia Garibaldi, n. 7. I-16124 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Bacigalupo","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, Radiology and Nuclear Medicine, EO Ospedali\nGalliera, Mura delle Cappuccine, n. 14. I-16128 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Luca","family":"Forni","sequence":"additional","affiliation":[{"name":"Centro\ndella Microcitemia, Anemie Congenite e Dismetabolismo del Ferro, EO Ospedali Galliera, Mura delle Cappuccine, n. 14. I-16128\nGenoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8460-0262","authenticated-orcid":true,"given":"Francesca","family":"Mattioli","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, EO Ospedali Galliera, Mura delle Cappuccine, n. 14. I-16128 Genoa, Italy"},{"name":"Department of Internal\nMedicine, Clinical Pharmacology and Toxicology Unit, University of Genoa, Viale Benedetto XV, n. 2. I-16132 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2147\/JBM.S72463","volume":"6","author":"Taher A.","year":"2015","unstructured":"Taher A.; Saliba A.N.; Harb A.; Iron chelation therapy in transfusion-dependent thalassemia patients: Current strategies and future directions. J Blood Med 2015,6,197-209","journal-title":"J Blood Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1053\/shem.2001.20142","volume":"38","author":"Ballas S.K.","year":"2001","unstructured":"Ballas S.K.; Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol 2001,38(Suppl. 1),30-36","journal-title":"Semin Hematol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.critrevonc.2014.01.006","volume":"91","author":"Temraz S.","year":"2014","unstructured":"Temraz S.; Santini V.; Musallam K.; Taher A.; Iron overload and chelation therapy in myelodysplastic syndromes. Crit Rev Oncol Hematol 2014,91(1),64-73","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000203853","volume":"95","author":"Gabutti V.","year":"1996","unstructured":"Gabutti V.; Piga A.; Results of long-term iron-chelating therapy. Acta Haematol 1996,95(1),26-36","journal-title":"Acta Haematol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11894-008-0024-9","volume":"9","author":"Barton J.C.","year":"2007","unstructured":"Barton J.C.; Chelation therapy for iron overload. Curr Gastroenterol Rep 2007,9(1),74-82","journal-title":"Curr Gastroenterol Rep"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/asheducation-2017.1.265","volume":"2017","author":"Taher A.T.","year":"2017","unstructured":"Taher A.T.; Saliba A.N.; Iron overload in thalassemia: Different organs at different rates. Hematology 2017,2017(1),265-271","journal-title":"Hematology"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1182\/blood-2012-05-370098","volume":"120","author":"Hoffbrand A.V.","year":"2012","unstructured":"Hoffbrand A.V.; Taher A.; Cappellini M.D.; How I treat transfusional iron overload. Blood 2012,120(18),3657-3669","journal-title":"Blood"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/ajh.25103","volume":"93","author":"Ballas S.K.","year":"2018","unstructured":"Ballas S.K.; Zeidan A.M.; Duong V.H.; DeVeaux M.; Heeney M.M.; The effect of iron chelation therapy on overall survival in sickle cell disease and \u03b2-thalassemia: A systematic review. Am J Hematol 2018,93(7),943-952","journal-title":"Am J Hematol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/MOH.0000000000000499","volume":"26","author":"Sheth S.","year":"2019","unstructured":"Sheth S.; Strategies for managing transfusional iron overload. Curr Opin Hematol 2019,26(3),139-144","journal-title":"Curr Opin Hematol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/ejh.13111","volume":"101","author":"Kattamis A.","year":"2018","unstructured":"Kattamis A.; Aydinok Y.; Taher A.; Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes. Eur J Haematol 2018,101(3),272-282","journal-title":"Eur J Haematol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","volume":"107","author":"Cappellini M.D.","year":"2006","unstructured":"Cappellini M.D.; Cohen A.; Piga A.; Bejaoui M.; Perrotta S.; Agaoglu L.; Aydinok Y.; Kattamis A.; Kilinc Y.; Porter J.; Capra M.; Galanello R.; Fattoum S.; Drelichman G.; Magnano C.; Verissimo M.; Athanassiou-Metaxa M.; Giardina P.; Kourakli-Symeonidis A.; Janka-Schaub G.; Coates T.; Vermylen C.; Olivieri N.; Thuret I.; Opitz H.; Ressayre-Djaffer C.; Marks P.; Alberti D.; A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006,107(9),3455-3462","journal-title":"Blood"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/j.1600-0609.2007.00985.x","volume":"80","author":"Porter J.","year":"2008","unstructured":"Porter J.; Galanello R.; Saglio G.; Neufeld E.J.; Vichinsky E.; Cappellini M.D.; Olivieri N.; Piga A.; Cunningham M.J.; Souli\u00e8res D.; Gattermann N.; Tchernia G.; Maertens J.; Giardina P.; Kwiatkowski J.; Quarta G.; Jeng M.; Forni G.L.; Stadler M.; Cario H.; Debusscher L.; Della Porta M.; Cazzola M.; Greenberg P.; Alimena G.; Rabault B.; Gathmann I.; Ford J.M.; Alberti D.; Rose C.; Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-yr prospective study. Eur J Haematol 2008,80(2),168-176","journal-title":"Eur J Haematol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3109\/03630260903217182","volume":"33","author":"Kontoghiorghes G.J.","year":"2009","unstructured":"Kontoghiorghes G.J.; A new era in iron chelation therapy: The design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients. Hemoglobin 2009,33(5),332-338","journal-title":"Hemoglobin"},{"year":"2022","key":"ref=14","unstructured":"ExjadeAvailable from: 2022"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s40262-014-0151-4","volume":"53","author":"Tanaka C.","year":"2014","unstructured":"Tanaka C.; Clinical pharmacology of deferasirox. Clin Pharmacokinet 2014,53(8),679-694","journal-title":"Clin Pharmacokinet"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/ajh.24668","volume":"92","author":"Taher A.T.","year":"2017","unstructured":"Taher A.T.; Origa R.; Perrotta S.; Kourakli A.; Ruffo G.B.; Kattamis A.; Goh A.S.; Cortoos A.; Huang V.; Weill M.; Merino Herranz R.; Porter J.B.; New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study. Am J Hematol 2017,92(5),420-428","journal-title":"Am J Hematol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/NAN.0000000000000278","volume":"41","author":"Tinsley S.M.","year":"2018","unstructured":"Tinsley S.M.; Hoehner-Cooper C.M.; Transitioning patients with iron overload from Exjade to Jadenu. J Infus Nurs 2018,41(3),171-175","journal-title":"J Infus Nurs"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40164-020-00174-2","volume":"9","author":"Tartaglione I.","year":"2020","unstructured":"Tartaglione I.; Origa R.; Kattamis A.; Pfeilst\u00f6cker M.; Gunes S.; Crowe S.; Fagan N.; Vincenzi B.; Ruffo G.B.; Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower\/intermediate risk MDS: Phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study. Exp Hematol Oncol 2020,9(1),20","journal-title":"Exp Hematol Oncol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"12581","DOI":"10.1038\/s41598-021-91983-w","volume":"11","author":"Piolatto A.","year":"2021","unstructured":"Piolatto A.; Berchialla P.; Allegra S.; De Francia S.; Ferrero G.B.; Piga A.; Longo F.; Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring. Sci Rep 2021,11(1),12581","journal-title":"Sci Rep"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/ejh.12419","volume":"94","author":"Mattioli F.","year":"2015","unstructured":"Mattioli F.; Puntoni M.; Marini V.; Fucile C.; Milano G.; Robbiano L.; Perrotta S.; Pinto V.; Martelli A.; Forni G.L.; Determination of deferasirox plasma concentrations: Do gender, physical and genetic differences affect chelation efficacy? Eur J Haematol 2015,94(4),310-317","journal-title":"Eur J Haematol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1111\/jphp.12638","volume":"68","author":"Allegra S.","year":"2016","unstructured":"Allegra S.; De Francia S.; Cusato J.; Pirro E.; Massano D.; Piga A.; D\u2019Avolio A.; Deferasirox pharmacokinetic and toxicity correlation in \u03b2-thalassaemia major treatment. J Pharm Pharmacol 2016,68(11),1417-1421","journal-title":"J Pharm Pharmacol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1182\/blood-2004-10-3982","volume":"106","author":"Wood J.C.","year":"2005","unstructured":"Wood J.C.; Enriquez C.; Ghugre N.; Tyzka J.M.; Carson S.; Nelson M.D.; Coates T.D.; MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005,106(4),1460-1465","journal-title":"Blood"},{"year":"1976","author":"James W.P.T.","key":"ref=23","unstructured":"James W.P.T.; Research on obesity; Her Majesty\u2019s Stationery Office, Press: London 1976"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0378-4347(01)00079-2","volume":"755","author":"Rouan M.C.","year":"2001","unstructured":"Rouan M.C.; Marfil F.; Mangoni P.; S\u00e9chaud R.; Humbert H.; Maurer G.; Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection. J Chromatogr, Biomed Appl 2001,755(1-2),203-213","journal-title":"J Chromatogr, Biomed Appl"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3390\/pharmaceutics13081238","volume":"13","author":"Galeotti L.","year":"2021","unstructured":"Galeotti L.; Ceccherini F.; Fucile C.; Marini V.; Di Paolo A.; Maximova N.; Mattioli F.; Evaluation of pharmacokinetics and pharmacodynamics of deferasirox in pediatric patients. Pharmaceutics 2021,13(8),1238","journal-title":"Pharmaceutics"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"106792","DOI":"10.1016\/j.leukres.2022.106792","volume":"114","author":"Pilo F.","year":"2022","unstructured":"Pilo F.; Cilloni D.; Della Porta M.G.; Forni G.L.; Piperno A.; Santini V.; Angelucci E.; Iron-mediated tissue damage in acquired ineffective erythropoiesis disease: It\u2019s more a matter of burden or more of exposure to toxic iron form? Leuk Res 2022,114,106792","journal-title":"Leuk Res"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1182\/blood-2010-11-316646","volume":"118","author":"Cappellini M.D.","year":"2011","unstructured":"Cappellini M.D.; Bejaoui M.; Agaoglu L.; Canatan D.; Capra M.; Cohen A.; Drelichman G.; Economou M.; Fattoum S.; Kattamis A.; Kilinc Y.; Perrotta S.; Piga A.; Porter J.B.; Griffel L.; Dong V.; Clark J.; Aydinok Y.; Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: Efficacy and safety during 5 years\u2019 follow-up. Blood 2011,118(4),884-893","journal-title":"Blood"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.2147\/TCRM.S170761","volume":"14","author":"Fucile C.","year":"2018","unstructured":"Fucile C.; Mattioli F.; Marini V.; Gregori M.; Sonzogni A.; Martelli A.; Maximova N.; What is known about deferasirox chelation therapy in pediatric HSCT recipients: Two case reports of metabolic acidosis. Ther Clin Risk Manag 2018,14,1649-1655","journal-title":"Ther Clin Risk Manag"},{"key":"ref=29","first-page":"873","volume":"91","author":"Piga A.","year":"2006","unstructured":"Piga A.; Galanello R.; Forni G.L.; Cappellini M.D.; Origa R.; Zappu A.; Donato G.; Bordone E.; Lavagetto A.; Zanaboni L.; Sechaud R.; Hewson N.; Ford J.M.; Opitz H.; Alberti D.; Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006,91(7),873-880","journal-title":"Haematologica"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"63177","DOI":"10.18632\/oncotarget.18725","volume":"8","author":"Maximova N.","year":"2017","unstructured":"Maximova N.; Gregori M.; Simeone R.; Sonzogni A.; Boz G.; Fucile C.; Marini V.; Martelli A.; Mattioli F.; Safety and tolerability of deferasirox in pediatric hematopoietic stem cell transplant recipients: One facility\u2019s five years\u2019 experience of chelation treatment. Oncotarget 2017,8(38),63177-63186","journal-title":"Oncotarget"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/01480545.2019.1660362","volume":"45","author":"Nafea O.E.","year":"2022","unstructured":"Nafea O.E.; Zakaria M.; Hassan T.; El Gebaly S.M.; Salah H.E.; Subclinical nephrotoxicity in patients with beta-thalassemia: Role of urinary kidney injury molecule. Drug Chem Toxicol 2022,45(1),93-102","journal-title":"Drug Chem Toxicol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"100594","DOI":"10.1016\/j.blre.2019.100594","volume":"38","author":"Pinto V.M.","year":"2019","unstructured":"Pinto V.M.; Poggi M.; Russo R.; Giusti A.; Forni G.L.; Management of the aging beta-thalassemia transfusion-dependent population-The Italian experience. Blood Rev 2019,38,100594","journal-title":"Blood Rev"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1182\/hematology.2019000036","volume":"2019","author":"Coates T.D.","year":"2019","unstructured":"Coates T.D.; Iron overload in transfusion-dependent patients. Hematology 2019,2019(1),337-344","journal-title":"Hematology"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1182\/blood-2019-125575","volume":"134","author":"Angelucci E.","year":"2019","unstructured":"Angelucci E.; Capasso M.; Della Porta M.G.; Forni G.L.; Girelli D.; Oliva E.N.; Pilo F.; Clavio M.; Riva M.; Pelizzari A.; Niscola P.; Cilloni D.; Binotto G.; Cris\u00e0 E.; Santini V.; A multicenter, italian trial of early iron chelation therapy with low dose deferasirox (Exjade\u00ae) in patients with low\/intermediate-1 risk MDS at the beginning of transfusional story. Blood 2019,134(Suppl. 1),4256-4256","journal-title":"Blood"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000494487","volume":"141","author":"Dou H.","year":"2019","unstructured":"Dou H.; Qin Y.; Chen G.; Zhao Y.; Effectiveness and safety of deferasirox in Thalassemia with iron overload: A meta-analysis. Acta Haematol 2019,141(1),32-42","journal-title":"Acta Haematol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"106381","DOI":"10.1016\/j.ijantimicag.2021.106381","volume":"58","author":"Castagnola E.","year":"2021","unstructured":"Castagnola E.; Cangemi G.; Mesini A.; Castellani C.; Martelli A.; Cattaneo D.; Mattioli F.; Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: A narrative review. Int J Antimicrob Agents 2021,58(3),106381","journal-title":"Int J Antimicrob Agents"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/j.addbeh.2012.09.015","volume":"38","author":"Marini V.","year":"2013","unstructured":"Marini V.; Fucile C.; Zuccoli M.L.; Testino G.; Sumberaz A.; Robbiano L.; Martelli A.; Mattioli F.; Involvement of the mu-opioid receptor gene polymorphism A118G in the efficacy of detoxification of alcohol dependent patients. Addict Behav 2013,38(3),1669-1671","journal-title":"Addict Behav"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389200224666221209144420","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/211838\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389200224666221209144420","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T18:16:51Z","timestamp":1692037011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/211838\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":37,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389200224666221209144420","relation":{},"ISSN":["1389-2002"],"issn-type":[{"type":"print","value":"1389-2002"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-08-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}